| In 000€ | Materialise
Medical |
Materialise
Software |
Materialise
Manufacturing |
Total
segments |
Unallocated (1) | Consolidated | ||||||||||||
| For the three months ended March 31, 2024 | ||||||||||||||||||
| Revenues | 26,183 |
|
10,438 |
|
27,016 |
|
63,637 |
|
0 |
|
63,637 |
|
||||||
| Segment (adj) EBITDA | 7,921 |
|
1,090 |
|
1,529 |
|
10,540 |
|
(2,446 |
) |
8,094 |
|
||||||
| Segment (adj) EBITDA % | 30.3 |
% |
10.4 |
% |
5.7 |
% |
16.6 |
% |
12.7 |
% |
||||||||
| For the three months ended March 31, 2023 | ||||||||||||||||||
| Revenues | 24,317 |
|
11,350 |
|
30,219 |
|
65,886 |
|
0 |
|
65,886 |
|
||||||
| Segment (adj) EBITDA | 7,348 |
|
2,427 |
|
3,189 |
|
12,964 |
|
(2,655 |
) |
10,310 |
|
||||||
| Segment (adj) EBITDA % | 30.2 |
% |
21.4 |
% |
10.6 |
% |
19.7 |
% |
15.6 |
% |
||||||||
| (1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA. |
